Terry Chrisomalis

All Posts

  • Inovio's Pipeline And Its Rise To Fame

    By Terry Chrisomalis - August 5, 2013 | Tickers: CLDX, INO, VICL

    There are many biotechs which are undervalued,because they are only in trials. But there are times when you can catch , if you look hard enough, at a gem biotech that is trading way below it's current value. This brings me to a biotech stock Inovio Pharmaceuticals Inc. (NYSEMKT: INO) This is one of a few biotech stocks that you can find that has a huge pipeline that trades more »

  • Biotechs With Prostate Cancer Treatments

    By Terry Chrisomalis - July 31, 2013 | Tickers: DNDN, JNJ, MDVN

    There are many types of biotech companies out there with tremendous value. Today, I will focus on the ones that target prostate cancer. Investors should look at these types of companies as they are starting to make good progress on their research. Another reason is that there is a huge billion dollar opportunity in this sector.

    When I say a billion dollar opportunity, I mean it literally. The sector is more »

  • Pharmacyclics Set to Glide Higher

    By Terry Chrisomalis - July 31, 2013 | Tickers: BIIB, JNJ, PCYC

    Pharmacyclics (NASDAQ: PCYC) has been a good company to invest in, especially if you had bought shares back in 2009 when it traded around $1 per share. That's not to say it is too late, because this biotech company still has a lot of room to run higher. The reason for the continued run up will be the pipeline that continues to produce results. All of the candidates in more »

  • Is Yahoo On The Brink of Collapsing?

    By Terry Chrisomalis - July 30, 2013 | Tickers: FB, GOOG, YHOO

    There are many good performing tech stocks for the year, but there is one that has gone up slightly. Yahoo (NASDAQ: YHOO)  has managed to go up by 78% from last July in 2012 till now! The reason for the appreciation was Yahoo's stake in the Alibaba business. Yahoo had put a new CEO in place to try,and turn the company around. So far though, there has been more »

  • Microsoft May Have Some Future Growth

    By Terry Chrisomalis - July 16, 2013 | Tickers: AMZN, MSFT, ORCL

    As we all know, Microsoft (NASDAQ: MSFT) has been a stagnant stock for a very long time. The return for Microsoft over the past 5 years has been a 31% increase in share price. During the same time the Dow Jones has gone up 44%. But despite that, picking almost any other technology stock would have yielded higher return during that time period. The good news going forward is that more »

  • RNAi Companies to Consider

    By Terry Chrisomalis - July 9, 2013 | Tickers: ALNY, ISIS, MRK

    RNAi and RNA companies had a terrible time when they were abandoned by big pharmaceutical companies. The abandonment came from the fact that both types of biotechs lacked proper delivery methods to get the RNA molecule strands to their target. Well it seems that this year all that has changed completely, as RNA therapeutics have been creating delivery methods to make their technologies work. Some RNA technologies use nanoparticles, lipids more »

  • Celldex On The Rise

    By Terry Chrisomalis - July 3, 2013 | Tickers: ARIA, CLDX, SGEN

    There are many biotech stocks that target cancer, but what is good about Celldex Therapeutics (NASDAQ: CLDX) is that it is targeting many therapeutic areas as well as cancer. Celldex has gone up over 209% in one year. The reason for the rise is the results that the company has been putting out about its drug candidates, especially two of them. The company has diversified its pipeline into targeting cancers more »

  • This Biotech Stock Looks Great for the Long Run

    By Terry Chrisomalis - June 30, 2013 | Tickers: MRK, OPK, PFE

    When you are looking to add a biotech stock to your portfolio, most of the small cap biotech stocks have a small-sized pipeline. Also, the small cap biotechs tend to target one area; for example, they may only target cancer. This brings up a biotech that will have substantial value in the future. This biotech company is known as Opko Health (NYSE: OPK) which has diversified itself in targeting many more »

  • Amgen's Future Is Bright

    By Terry Chrisomalis - June 29, 2013 | Tickers: AMGN, PFE, TEVA

    Amgen (NASDAQ: AMGN) has gone up a lot in share price over the last few years. Amgen has climbed up 91% over the past three years, leaving long-term investors with a lot of gains. In the same time period the Dow Jones has only gone up 64%. Despite the big run, the company can still see its share price rise higher in the coming years. The company has been known more »

  • Innovation at Apple: Fact or Fiction?

    By Terry Chrisomalis - June 23, 2013 | Tickers: AAPL, GOOG, P

    The last time we heard CEO Tim Cook introduce Apple (NASDAQ: AAPL) products at a convention was eight months ago. Apple recently announced news about iRadio, a new service that the company is bringing to its users. So what is the problem with this new radio service? Basically, it is the same in essence as other music service competitors that exist on the market. Apple is having trouble innovating with more »

  • Big Bank Theory

    By Terry Chrisomalis - June 21, 2013 | Tickers: BAC, JPM, WFC

    It seems that the big banks have been rebounding in the stock market, and while there were many problems in the past, it seems there is now a turnaround. The banks that have been called "too big to fail" are: Bank of America (NYSE: BAC), JPMorgan (NYSE: JPM), and Wells Fargo (NYSE: WFC). With such huge risk, why should investors take a look at these stocks? The answer is quite more »

  • ASCO Stocks That Should Sizzle in the Future

    By Terry Chrisomalis - June 9, 2013 | Tickers: BMY, CLVS, MRK

    Every year, there is a big event for pharmaceutical companies known as ASCO. ASCO is the American Society Of Clinical Oncology, in which pharmaceutical companies post results on cancer trials. There were many companies that posted amazing results this time, but here, I will highlight three of them which will might be good for your portfolio in the long-term. The three pharmaceutical stocks to own for the long run are more »

  • Pfizer's Big Chance

    By Terry Chrisomalis - June 6, 2013 | Tickers: LLY, GSK, PFE, VVUS

    When we think of big pharma companies, the company we think about constantly is Pfizer (NYSE: PFE), especially as the company recently announced it will start selling Viagra online. This is a bold move, and I think that Pfizer has the financial backing to make it work. 

    There are other problems that Pfizer has to deal with here, like counterfeit pills from online pharmacies. Pfizer knows that this problem will more »

  • Wal-Mart Is Reaching New Heights

    By Terry Chrisomalis - June 4, 2013 | Tickers: M, TGT, WMT

    When you think of successful retail stores there is one name that always comes to mind: Wal-Mart (NYSE: WMT). Wal-Mart started off small at first, when it launched back in 1962. Since then Wal-Mart has seen many customers shop at its store for competitive prices not seen at other retail stores. Wal-Mart had reported total sales for the fiscal year that ended in January of $466 billion. This was a more »

  • This Chinese Company Is Worth Your Attention

    By Terry Chrisomalis - May 29, 2013 | Tickers: FB, RENN, SINA

    There is one Chinese company worth buying as the market continues to edge to higher levels: SINA (NASDAQ: SINA). This company still has a long way to go to monetize its assets, so short-term the trade is very risky. Although if you are a long-term investor then this is a good position to get into for future profit. 

    The company boasts a market cap of $3.9 billion, and with more »

  • Can These Stocks Deliver profits?

    By Terry Chrisomalis - May 15, 2013 | Tickers: FDX, LEN, UPS

    When we want to ship a package there are only a few options to choose. One of those options is the United States Postal Service, or USPS; an affordable way for those people who don't need to deliver their packages quickly, and want cheaper standard shipping options. But the USPS has seen some problems in funding from the government, and people prefer to use other shipping service methods. 

    Two more »

  • This Stock Should Get Better in the Long Run

    By Terry Chrisomalis - May 15, 2013 | Tickers: ACAD, MRK, PFE

    ACADIA Pharmaceuticals (NASDAQ: ACAD) has been on a solid run since early last year and it has continued to climb to new highs this year as well. The move that started it all happened in late 2012. On Nov. 27, 2012, ACADIA had announced that their drug, Pimavanserin, had met both primary and secondary endpoints. This trial completed was the pivotal phase 3 trial for Parkinson disease Psychosis. 

    So, as more »

  • Galena: Improving Cancer Vaccines for the Future

    By Terry Chrisomalis - May 7, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for breast cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Galena Improving Cancer Vaccines For The Future

    By Terry Chrisomalis - May 1, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for Breast Cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Apple Has Lost Its Way

    By Terry Chrisomalis - May 1, 2013 | Tickers: AAPL, GOOG, NFLX

    Apple (NASDAQ: AAPL)) hit its high of $700 per share in after-hours trading on Sept. 17, 2012. What has happened since then hasn't been favorable for the tech giant at all. So what has gone wrong for Apple, and why has it declined in value so much? It seems that Apple is losing its way of innovating and creating products that fans would love to buy. 

    Let us take more »

  • Page 1 of 3